04. Zymeworks Inc. (ZYME) 2024年第四季度财报电话会议：Zymeworks是一家专注于开发多功能生物治疗药物的临床阶段生物技术公司，其2024年净亏损1.227亿美元，收入从2023年的7600万美元略增至7630万美元。公司拥有多个临床前和临床阶段的项目，包括ZW191（FRα靶向ADC）和ZW251（GPC3靶向ADC），后者在肝细胞癌模型中表现出色，预计2025年 ...

Despite posting disappointing top revenue and earnings misses for Q4 last week, Zymeworks (ZYME) has seen its shares rally over 5%, thanks in ...

Analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Zymeworks in a research note issued to investors on ...

LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...

Zymeworks Inc (ZYME) navigates a challenging year with strategic pivots and robust partnership earnings, despite increased ...

周四，花旗分析师将纳斯达克上市公司Zymeworks（NASDAQ:ZYME）的目标股价从此前的18美元上调至19美元，同时重申对该公司股票的买入评级。目前该股交易价格为13.18美元，低于分析师12美元至30美元的目标区间。根据 InvestingPro 数据显示，尽管该公司仍处于开发阶段，但其整体财务健康状况评分为"良好"，表明基本面稳健。

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares ...

Zymeworks Inc. (ZYME) shares soared 5.4% in the last trading session to close at $11.70. The move was backed by solid volume with far more shares changing hands than in a normal session.

Capital, LLC EcoR1, a director at $ZYME, bought 468,356 shares of the company on 03-13-2025 for an estimated $5,847,237. This trade was reported by Quiver ...

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.31 per share versus the Zacks Consensus Estimate of a loss of $0.32. This compares to loss of $0.20 per share a year ago. These figures ...